Previous 10 | Next 10 |
CTI BioPharma has finally fulfilled its long sought goal of FDA approval for its VONJO (JAK inhibitor pacritinib) in treatment of myelofibrosis. Armed with a wholesale cost of ~$19,500 month, VONJO could be a blockbuster. CTI's market cap of ~$0.681 leaves room for upside if it ca...
CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi. While the potential is huge, cash and some data points are worrying signs. CTI BioPharma Corp. ( CTIC ) was granted accelerated approval of VONJO or pac...
Stocks climbed on Thursday, adding to gains posted the previous day. Tech and consumer discretionary stocks helped lead the rally, with the Nasdaq rising more than 2%. Solar and clean energy stocks found themselves in the vanguard of Thursday's advance. Stocks like Daqo New Energy ( D...
The stock of CTI BioPharma (NASDAQ: CTIC) was an outlier in the biotech sector on Thursday, and in the best way possible. The company's shares surged more than 18% higher on the day, following a new and bullish analyst note on the company based on positive anecdotal evidence. Th...
Cowen has initiated CTI Biopharma ( NASDAQ: CTIC ) with an outperform rating citing the growth potential of Vonjo (pacritinib), which was approved in February for thrombocytopenic myelofibrosis. Shares are up 14% in Thursday afternoon trading. The firm has a $10 pr...
CTI BioPharma (NASDAQ:CTIC), a commercial-stage biotech focused on blood-related cancers, dropped ~9% in the pre-market Friday after the company disclosed data for its FDA-approved therapy pacritinib from patients with myelofibrosis and thrombocytopenia. The data from Phase 3 PERSIS...
DocuSign (DOCU) -25% on Q1 earnings release. RISE Education Cayman (REDU) -24%. Stitch Fix (SFIX) -15% on FQ3 earnings release. DBV Technologies (DBVT) -15%. Caribou Biosciences (CRBU) -13% amid new data for CAR-T therapy for non-Hodgkin lymphoma. Applied UV (AUV...
CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress PR Newswire SEATTLE , June 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced two scientific poster presentatio...
Commercial stage biotech CTI Biopharma (CTIC) has added ~19% in morning hours Wednesday to post the biggest intraday gain since March and reach a 52-week high on above-average volume of shares. The small-cap stock has ranked among the best performers in healthcare, with over 4.9M sh...
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
News, Short Squeeze, Breakout and More Instantly...
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders PR Newswire SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization ...
Shares of CTI BioPharma Corp. (NASDAQ: CTIC) traded at a new 52-week high today and are currently trading at $8.99. So far today, approximately 1.79M shares have been exchanged, as compared to an average 30-day volume of 10.16M shares. CTI BioPharma Corp., a biopharmaceutical company, focuses...
NEW YORK, NY / ACCESSWIRE / May 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ: FRG)'s ...